Corpus 1,273 assessed · 1,174 scored · 643 reproduced ≥75 · 169 flagged ·∅ 74.1/100

Publications 3 Datasets 392.5k Experiments 4.7k

Explore

Filters: Cell Rep Med ✕ 1 ✕ other ✕ clear all

3 matching publication(s)

Publication	Journal	Year	Score	Verdict
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104). PMID 38897205	Cell Rep Med	2024	72	L1 72/100
Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight. PMID 35028613	Cell Rep Med	2021	75	L1 75/100
Vaccine-induced ICOS+CD38+ circulating Tfh are sensitive biosensors of age-related changes in inflammatory pathway PMID 34095875	Cell Rep Med	2021	88	L1 88/100

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).

PMID 38897205 · Cell Rep Med · 2024

L1 72/100

Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight.

PMID 35028613 · Cell Rep Med · 2021

L1 75/100

Vaccine-induced ICOS+CD38+ circulating Tfh are sensitive biosensors of age-related changes in inflammatory pathway

PMID 34095875 · Cell Rep Med · 2021

L1 88/100